Q4 2024 Dishman Carbogen Amcis Ltd Earnings Call Transcript
Key Points
- Dishman Carbogen Amcis Ltd (BOM:540701) successfully resolved all issues highlighted by the EDQM and passed the audit with flying colors.
- The company also passed the USFDA audit with minimal recommendations, ensuring compliance and stability in key markets.
- Carbogen Amcis Group achieved a record turnover of over CHF0.25 billion for the first time in its history.
- The company is receiving a significant number of inquiries for new projects, indicating a bright future and potential growth.
- Dishman Carbogen Amcis Ltd (BOM:540701) has completed major CapEx projects and is now focusing on digital transformation to enhance productivity.
- The company faced unexpected challenges with the USFDA audit, which slowed down production and manufacturing capabilities.
- Despite resolving operational issues, the company did not meet its ambitious budget targets, resulting in a slightly lower EBITDA.
- The geopolitical situation has made it difficult for small biotech companies in Europe to raise money, affecting some of Dishman Carbogen Amcis Ltd (BOM:540701)'s customers.
- The French facility experienced significant operational issues, including machine failures, leading to a negative EBITDA impact of INR47 crores for the quarter.
- The company has faced consistent one-off expenses, including IT project costs, employee remuneration corrections, and maintenance expenditures, which have impacted financial performance.
Ladies and gentlemen, good day, and welcome to Dishman Carbogen Amcis Limited Q4 FY24 earnings conference call. (Operator Instructions) Please note that this conference is being recorded. I now hand the conference over to Mr. Arpit Vyas, Global Managing Director, Dishman Carbogen Amcis. Thank you, and over to you, sir.
Thank you, moderator. Good morning, everyone. It is a pleasure to have you all for our yearly conference call. It has been an exciting five-year journey. But in that journey, we have the tremendous effort from the people and tremendous hard work was to put in through all the challenging times of COVID and also the war and the global uncertainty that still exists today.
Through all this difficult period, we were unfortunate enough to, as you all know, get the observations from the European authorities, which made it challenging for us to do any business in Europe. For that, we took up the challenge of resolving the entire issues highlighted by the EDQM
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
